Bolt Biotherapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Bolt Biotherapeutics, Inc. - overview
Established
2015
Location
Redwood City, CA, US
Primary Industry
Biotechnology
About
Based in the US and founded in 2015 by Dr. Edgar G. Engleman, Bolt Biotherapeutics, Inc. is a biotechnology company that develops Boltbody, an immuno-oncology therapeutics designed to leverage the power of the innate and adaptive immune system.
Bolt Biotherapeutics, Inc. offers a broad spectrum of antibodies targeting tumor antigens on all types of cancer that applicable to any type of patient. Bolt Biotherapeutics, Inc. expands the Executive Team and appointed Kathleen LaPorte as one of the Board of Directors.
Current Investors
Vivo Capital, Novo Holdings, Pivotal Life Sciences
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.boltbio.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.